- Trial phase
- Approved
- Time to market
- Already approved and marketed since August 2021. The latest seasonal strain update (2026-2027 XFG formula) was approved August 27, 2026 and is currently available.
- Why 3/10
- Comirnaty is an approved, marketed product with no pending PDUFA or pivotal readout in the next 12 months. The most recent binary catalyst (the 2026-2027 XFG formula sBLA approval) already passed on August 27, 2026. Per the rubric, an approved drug with no pending regulatory decision scores 3-5. Comirnaty is also a declining revenue contributor for Pfizer (combined COVID products ~7.6% of Q3 2026 revenue), further limiting its standalone share-price impact.
Comirnaty has no pending PDUFA or pivotal readout; the 2026-2027 seasonal strain update was already approved in August 2026. Watch Q4 2026 vaccination-season sales (management expects the majority of Comirnaty revenue in Q4) and any FDA VRBPAC meetings in mid-2027 that set the next seasonal strain composition. For Pfizer stock, Comirnaty's trajectory is a slow fade; the more important drivers are the non-<|image|>COVID pipeline (oncology, vaccines) and the raised $62-64B full-year revenue guidance.
Price Chart
Executive Summary
Comirnaty (tozinameran / BNT162b2) is Pfizer and BioNTech's mRNA COVID-19 vaccine, first fully FDA-approved in August 2021. The most recent strain update, the 2026-2027 XFG formula (Comirnaty XFG), was approved by the FDA on August 27, 2026 for adults 65+ and high-risk individuals ages 5-64. Comirnaty is now a mature, seasonal product with declining revenue: combined COVID products (Comirnaty + Paxlovid) made up only about 7.6% of Pfizer's Q3 2026 revenue, and full-year 2026 COVID product guidance is roughly $4 billion. Pfizer's non-COVID business is growing strongly, offsetting the COVID revenue decline. No upcoming binary catalyst exists for this drug.
How It Works
Comirnaty is an mRNA vaccine that instructs cells to produce a harmless piece of the spike protein found on the surface of the SARS-CoV-2 virus. The immune system recognizes this protein as foreign and builds antibodies and T-cell responses against it, so if the vaccinated person is later exposed to the actual virus, their immune system is primed to fight it off and prevent COVID-19 disease.
Trial Status
Comirnaty received full FDA approval on August 23, 2021 for ages 16 and older, the first COVID-19 vaccine to achieve that milestone. Since then, the FDA has approved multiple updated seasonal formulations targeting emerging variants. The most recent, the 2026-2027 XFG formula (Comirnaty XFG), was approved on August 27, 2026 for adults 65+ and individuals ages 5-64 with high-risk conditions. The prior EUA for the original formulation was revoked on August 27, 2025.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 vaccination-season sales results (majority of Comirnaty annual revenue expected in Q4)
- Potential FDA VRBPAC meeting in mid-2027 to select 2027-2028 seasonal strain composition
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report